Aptorum Group Limited(APM)Earnings, Financials & Key Ratios
APM•NASDAQ
Price updated Jun 19, 2026
AboutAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.Show more
- Revenue$0-100.0%
- EBITDA-$4M+62.6%
- Net Income-$4M-51.1%
- EPS (Diluted)-0.78-25.8%
- ROE-31.43%-29.1%
APM Key Insights
Aptorum Group Limited (APM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 20.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when APM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APM Price & Volume
Aptorum Group Limited (APM) stock price & volume — 10-year historical chart
Loading chart...
APM Growth Metrics
Aptorum Group Limited (APM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-84.8%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM79.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM82.83%
Return on Capital
10 Years-61.09%
5 Years-73.99%
3 Years-79.69%
Last Year-25.03%
APM Peer Comparison
Aptorum Group Limited (APM) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 ZLAB | 2.01B | 18.18 | -11.36 | 15.33% | -39.29% | -24.32% | 0.31 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 | |
 AYTU | 18.71M | 2.31 | -1.07 | 1.84% | -60.17% | -148.91% | 1.21 | |
 CLOV | 2.59B | 5.00 | -29.41 | 40.34% | -2.58% | -17.08% | ||
 HCM | 1.79B | 10.28 | 3.95 | -12.73% | 77.53% | 46.37% | 0.08 | |
 CNTB | 125.93M | 2.00 | -2 | -99.75% | -88.76% | -27.94% | 0.02 |
Compare APM vs Peers
Aptorum Group Limited (APM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APM Income Statement
Aptorum Group Limited (APM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 383.45K | 535.17K | 911.51K | 1.54M | 1.3M | 431.38K | 0 |
Revenue Growth % | - | - | 39.57% | 70.32% | 69.17% | -15.95% | -66.71% | -100% |
Cost of Goods Sold | 58.9K | 318.01K | 794.54K | 1.01M | 1.46M | 1.22M | 420.81K | 255.05K |
COGS % of Revenue | - | 82.93% | 148.47% | 111.35% | 94.68% | 93.83% | 97.55% | - |
Gross Profit | -58.9K▲ 0% | 65.44K▲ 211.1% | -259K▼ 495.8% | -104K▲ 59.8% | 81.85K▲ 178.7% | 80.06K▼ 2.2% | 10.57K▼ 86.8% | -255K▼ 2513.4% |
Gross Margin % | - | 17.07% | -48.4% | -11.41% | 5.31% | 6.18% | 2.45% | - |
Gross Profit Growth % | - | 211.1% | -495.79% | 59.85% | 178.71% | -2.19% | -86.8% | -2513.4% |
Operating Expenses | 5.63M | 10.39M | -259K | 20.17M | 19.29M | 17.25M | 10.61M | 3.54M |
OpEx % of Revenue | - | 2710.65% | -48.4% | 2213.03% | 1250.91% | 1331.33% | 2460.02% | - |
Selling, General & Admin | 2.88M | 6.73M | 10.78M | 7.71M | 8.03M | 7.97M | 4.42M | 1.47M |
SG&A % of Revenue | - | 1755.38% | 2014.14% | 845.63% | 520.56% | 614.59% | 1023.46% | - |
Research & Development | 2.5M | 3.1M | 6.94M | 11.59M | 10.87M | 9.22M | 5.2M | 1.94M |
R&D % of Revenue | - | 808.71% | 1296.61% | 1271.19% | 704.93% | 711.42% | 1204.98% | - |
Other Operating Expenses | 257K | -9.77M | -17.98M | 877K | 392K | 68.95K | 999K | 128K |
Operating Income | -5.69M▲ 0% | -10.33M▼ 81.4% | -18.2M▼ 76.2% | -19.89M▼ 9.3% | -19.21M▲ 3.5% | -17.51M▲ 8.8% | -10.6M▲ 39.5% | -3.8M▲ 64.2% |
Operating Margin % | - | -2693.44% | -3400.44% | -2182.63% | -1245.59% | -1351.01% | -2457.47% | - |
Operating Income Growth % | - | -81.42% | -76.2% | -9.32% | 3.46% | 8.84% | 39.45% | 64.19% |
EBITDA | -5.63M | -9.65M | -16.9M | -18.56M | -18.01M | -16.3M | -9.48M | -3.54M |
EBITDA Margin % | - | -2515.51% | -3157.53% | -2036.17% | -1168.22% | -1257.8% | -2196.68% | - |
EBITDA Growth % | - | -71.2% | -75.19% | -9.83% | 2.94% | 9.51% | 41.87% | 62.63% |
D&A (Non-Cash Add-back) | 58.9K | 682.29K | 1.3M | 1.33M | 1.19M | 1.21M | 1.13M | 255.05K |
EBIT | -2.56M | -10.68M | -16.42M | 5.16M | -27.02M | -11.53M | -10.6M | -4.01M |
Net Interest Income | 0 | -4.46M | -3.7M | -244K | -93.6K | 146.59K | -121K | -147K |
Interest Income | 44.27K | 0 | 0 | 0 | 0 | 146.59K | 0 | 0 |
Interest Expense | 0 | 4.46M | 3.7M | 243.63K | 93.6K | 0 | 121.14K | 146.92K |
Other Income/Expense | 3.13M | -4.81M | -1.92M | 0 | -7.91M | 5.98M | 6.26M | -361K |
Pretax Income | -2.56M▲ 0% | -15.13M▼ 490.7% | -20.12M▼ 32.9% | 4.92M▲ 124.5% | -27.11M▼ 651.1% | -11.53M▲ 57.5% | -4.34M▲ 62.3% | -4.16M▲ 4.2% |
Pretax Margin % | - | -3946.8% | -3759.02% | 539.76% | -1758.37% | -889.27% | -1006.31% | - |
Income Tax | -14.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.55% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.55M▲ 0% | -14.83M▼ 482.3% | -18.69M▼ 26.0% | 7.07M▲ 137.8% | -25.05M▼ 454.4% | -9.8M▲ 60.9% | -2.83M▲ 71.2% | -4.27M▼ 51.1% |
Net Margin % | - | -3868.04% | -3491.81% | 775.31% | -1624.38% | -756.17% | -654.88% | - |
Net Income Growth % | - | -482.33% | -25.99% | 137.82% | -454.44% | 60.88% | 71.17% | -51.08% |
Net Income (Continuing) | -2.56M | -15.13M | -20.12M | 4.92M | -27.11M | -11.53M | -4.34M | -4.16M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -14.04K | -368.53K | -1.51M | -3.68M | -6.1M | -7.88M | -9.46M | -9.36M |
EPS (Diluted) | -0.85▲ 0% | -5.31▼ 524.7% | -6.40▼ 20.5% | 2.00▲ 131.3% | -7.15▼ 457.5% | -2.75▲ 61.5% | -0.62▲ 77.5% | -0.78▼ 25.8% |
EPS Growth % | - | -524.71% | -20.53% | 131.25% | -457.5% | 61.54% | 77.45% | -25.81% |
EPS (Basic) | -0.85 | -5.31 | -6.40 | 2.03 | -7.15 | -2.75 | -0.62 | -0.78 |
Diluted Shares Outstanding | 3.01M | 2.79M | 2.9M | 3.15M | 3.5M | 3.57M | 4.52M | 5.45M |
Basic Shares Outstanding | 3.01M | 2.79M | 2.9M | 3.11M | 3.5M | 3.57M | 4.52M | 5.45M |
Dividend Payout Ratio | - | - | - | 10.69% | - | - | - | - |
APM Balance Sheet
Aptorum Group Limited (APM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 20.28M | 28.72M | 8.03M | 33.66M | 12.69M | 7.07M | 2.48M | 959.55K |
Cash & Short-Term Investments | 18.22M | 13.02M | 6.25M | 31.88M | 8.5M | 1.99M | 2.01M | 874.24K |
Cash Only | 16.25M | 12.01M | 5.19M | 3.5M | 8.13M | 1.88M | 2.01M | 874.24K |
Short-Term Investments | 1.97M | 1.01M | 1.06M | 28.38M | 236.62K | 102.48K | 0 | 0 |
Accounts Receivable | 179.49K | 990.85K | 487.59K | 341.06K | 3.56M | 1.18M | 70.94K | 4.54K |
Days Sales Outstanding | - | 943.17 | 332.55 | 136.57 | 842.9 | 332.53 | 60.03 | - |
Inventory | 1.54M | 30.64K | 34.19K | 39.13K | 35.77K | 27.72K | 0 | 0 |
Days Inventory Outstanding | 9.52K | 35.17 | 15.7 | 14.07 | 8.94 | 8.32 | - | - |
Other Current Assets | 99.58K | 14.22M | 309.03K | 135.95K | 71.2K | 3.34M | 0 | 0 |
Total Non-Current Assets | 11.28M | 16.35M | 15.92M | 10.57M | 9.22M | 13.8M | 18.16M | 15.17M |
Property, Plant & Equipment | 346.59K | 4.26M | 7.09M | 5.38M | 4.03M | 3.17M | 1.85M | 0 |
Fixed Asset Turnover | - | 0.09x | 0.08x | 0.17x | 0.38x | 0.41x | 0.23x | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 1.47M | 1.41M | 1.31M | 964.86K | 880.26K | 752.71K | 147.35K | 0 |
Long-Term Investments | 7.39M | 7.09M | 7.11M | 4.08M | 4.16M | 9.74M | 16.1M | 15.1M |
Other Non-Current Assets | 2.06M | 119.67K | 59.83K | 149.18K | 149.18K | 127.3K | 71.82K | 71.82K |
Total Assets | 31.56M▲ 0% | 45.07M▲ 42.8% | 23.95M▼ 46.9% | 44.23M▲ 84.6% | 21.91M▼ 50.5% | 20.87M▼ 4.7% | 20.64M▼ 1.1% | 16.13M▼ 21.9% |
Asset Turnover | - | 0.01x | 0.02x | 0.02x | 0.07x | 0.06x | 0.02x | - |
Asset Growth % | - | 42.82% | -46.86% | 84.65% | -50.47% | -4.75% | -1.09% | -21.85% |
Total Current Liabilities | 1.33M | 12.18M | 2.67M | 3.87M | 4.38M | 12.5M | 2.1M | 4.34M |
Accounts Payable | 0 | 40.14K | 0 | 0 | 0 | 0 | 0 | 0 |
Days Payables Outstanding | - | 46.07 | - | - | - | - | - | - |
Short-Term Debt | 480K | 10.11M | 0 | 627.92K | 204.7K | 6.01M | 204.41K | 3.24M |
Deferred Revenue (Current) | 0 | 1.24M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 811.93K | 55.48K | -627.92K | -204.7K | 0 | -204.41K | 0 |
Current Ratio | 15.24x | 2.36x | 3.00x | 8.70x | 2.90x | 0.57x | 1.18x | 0.22x |
Quick Ratio | 14.09x | 2.35x | 2.99x | 8.69x | 2.89x | 0.56x | 1.18x | 0.22x |
Cash Conversion Cycle | - | 932.27 | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 143.87K | 6.43M | 2.21M | 23.85K | 530.78K | 3.16M | 14.18K |
Long-Term Debt | 0 | 0 | 6.33M | 2.01M | 0 | 500K | 3.06M | 0 |
Capital Lease Obligations | 0 | 143.87K | 97.32K | 203.04K | 23.85K | 30.78K | 99.48K | 14.18K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.33M | 12.33M | 9.1M | 6.08M | 4.4M | 13.03M | 5.26M | 4.35M |
Total Debt | 480K | 10.3M | 6.47M | 3.32M | 217.17K | 6.85M | 3.49M | 3.35M |
Net Debt | -15.77M | -1.71M | 1.29M | -174.98K | -7.91M | 4.97M | 1.48M | 2.48M |
Debt / Equity | 0.02x | 0.31x | 0.44x | 0.09x | 0.01x | 0.88x | 0.23x | 0.28x |
Debt / EBITDA | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - |
Interest Coverage | - | -2.32x | -4.92x | -81.66x | -205.20x | - | -87.51x | -25.84x |
Total Equity | 30.23M▲ 0% | 32.75M▲ 8.3% | 14.85M▼ 54.6% | 38.15M▲ 156.9% | 17.51M▼ 54.1% | 7.83M▼ 55.3% | 15.38M▲ 96.4% | 11.78M▼ 23.4% |
Equity Growth % | - | 8.33% | -54.65% | 156.89% | -54.12% | -55.25% | 96.38% | -23.44% |
Book Value per Share | 10.04 | 11.73 | 5.12 | 12.10 | 5.00 | 2.19 | 3.40 | 2.16 |
Total Shareholders' Equity | 30.24M | 33.11M | 16.36M | 41.83M | 23.61M | 15.71M | 24.85M | 21.13M |
Common Stock | 27.86M | 28.98M | 29.04M | 34.02M | 35.64M | 35.71M | 53 | 55 |
Retained Earnings | -2.55M | -17.38M | -37.56M | -30.49M | -55.54M | -65.34M | -68.16M | -72.43M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -367.78K | -1.48M | -5.55K | 53.3K | -2.02K | 33.81K | -10.62K | 89.16K |
Minority Interest | -14.04K | -368.53K | -1.51M | -3.68M | -6.1M | -7.88M | -9.46M | -9.36M |
APM Cash Flow Statement
Aptorum Group Limited (APM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.78M | -10.04M | -13.38M | -15.93M | -14.65M | -12.32M | -7.72M | -1.19M |
Operating CF Margin % | - | -2617.17% | -2500.65% | -1747.86% | -950.17% | -950.54% | -1790.63% | - |
Operating CF Growth % | - | -73.54% | -33.35% | -19.05% | 8.04% | 15.92% | 37.3% | 84.58% |
Net Income | -2.55M | -15.13M | -20.12M | 4.92M | -27.11M | -11.53M | -4.34M | -4.27M |
Depreciation & Amortization | 58.9K | 682.29K | 1.3M | 1.33M | 1.19M | 1.21M | 1.13M | 255.05K |
Stock-Based Compensation | 0 | 0 | 1.61M | 1.48M | 1.68M | 1.65M | 1.27M | 0 |
Deferred Taxes | 0 | 0 | -1.53M | -24.46M | 7.96M | 0 | 0 | 0 |
Other Non-Cash Items | -2.93M | 4.81M | 4.14M | 751.03K | 609.34K | -5.05M | -6.18M | 3.03M |
Working Capital Changes | -195.09K | -389.73K | 1.22M | 45.55K | 1.02M | 1.4M | 407.07K | -211.1K |
Change in Receivables | -48.01K | -2.83K | -37.72K | -21.68K | -16.5K | -171.91K | 417.22K | 41.35K |
Change in Inventory | 0 | -30.64K | -3.54K | -4.95K | 3.36K | 8.05K | 14.52K | 0 |
Change in Payables | 0 | 58.55K | 986.24K | 800.96K | 855.27K | 1.92M | 398.63K | 0 |
Cash from Investing | 12.8M | -6.06M | -108.06K | 1.84M | 16.51M | 2.44M | 624.77K | 58.62K |
Capital Expenditures | -3.06M | -6.06M | -1.11M | -161.31K | -137.78K | -186.92K | -3.02K | 0 |
CapEx % of Revenue | - | 1581.51% | 206.88% | 17.7% | 8.93% | 14.42% | 0.7% | - |
Acquisitions | 0 | 417.79K | 270.11K | 25.24M | -113.83K | 0 | 15.38K | 58.62K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -186.9K | 83.73K | -70.11K | 1.05M | -3.35M | 2.5M | 519.18K | 0 |
Cash from Financing | 9.08M | 25.48M | -7.32M | 12.42M | 2.78M | 6.63M | 4.09M | 1.43K |
Debt Issued (Net) | 480K | 16.06M | -7.32M | -4.36M | -2.04M | 6.45M | 2.55M | 1.43K |
Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 5.36K | 1000K | 0 |
Dividends Paid | 0 | 0 | 0 | -755.51K | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -1.64M | 0 | 40.42K | 824.24K | 169.46K | -54.53K | 0 |
Net Change in Cash | 16.1M▲ 0% | 9.38M▼ 41.7% | -20.81M▼ 321.9% | -1.67M▲ 92.0% | 4.64M▲ 378.0% | -3.25M▼ 170.1% | -3.01M▲ 7.4% | -1.13M▲ 62.4% |
Free Cash Flow | -8.84M▲ 0% | -16.1M▼ 82.1% | -14.49M▲ 10.0% | -16.09M▼ 11.1% | -14.79M▲ 8.1% | -12.51M▲ 15.4% | -7.73M▲ 38.2% | -1.19M▲ 84.6% |
FCF Margin % | - | -4198.68% | -2707.53% | -1765.56% | -959.11% | -964.96% | -1791.32% | - |
FCF Growth % | - | -82.08% | 10% | -11.07% | 8.1% | 15.44% | 38.21% | 84.59% |
FCF per Share | -2.94 | -5.77 | -4.99 | -5.10 | -4.22 | -3.50 | -1.71 | -0.22 |
FCF Conversion (FCF/Net Income) | 2.27x | 0.68x | 0.72x | -2.25x | 0.58x | 1.26x | 2.73x | 0.28x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
APM Key Ratios
Aptorum Group Limited (APM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -8.43% | -47.1% | -78.52% | 26.67% | -90.01% | -77.35% | -24.34% | -31.43% |
Return on Invested Capital (ROIC) | -29.52% | -34.05% | -57.87% | -55.15% | -60.57% | -117.26% | -53.59% | -18.29% |
Gross Margin | - | 17.07% | -48.4% | -11.41% | 5.31% | 6.18% | 2.45% | - |
Net Margin | - | -3868.04% | -3491.81% | 775.31% | -1624.38% | -756.17% | -654.88% | - |
Debt / Equity | 0.02x | 0.31x | 0.44x | 0.09x | 0.01x | 0.88x | 0.23x | 0.28x |
Interest Coverage | - | -2.32x | -4.92x | -81.66x | -205.20x | - | -87.51x | -25.84x |
FCF Conversion | 2.27x | 0.68x | 0.72x | -2.25x | 0.58x | 1.26x | 2.73x | 0.28x |
Revenue Growth | - | - | 39.57% | 70.32% | 69.17% | -15.95% | -66.71% | -100% |
Related:APM Dividend History·APM Revenue History·APM Price History·APM P/E History·APM Financial Ratios·APM Institutional Holders
APM Frequently Asked Questions
Aptorum Group Limited (APM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aptorum Group Limited (APM) reported $0.4M in revenue for fiscal year 2024.
Aptorum Group Limited (APM) saw revenue decline by 100.0% over the past year.
Aptorum Group Limited (APM) reported a net loss of $7.1M for fiscal year 2024.
Dividend & Returns
Aptorum Group Limited (APM) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.
Aptorum Group Limited (APM) had negative free cash flow of $9.0M in fiscal year 2024, likely due to heavy capital investments.